Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Table 2 Characteristics of expanded cells

Patient no.	CD3⁻CD56⁺	CD3⁺CD56⁺	CD3⁺CD4⁺	CD3⁺CD8⁺	NKG2D+ in CD3⁻CD56⁺	CD16+ in CD3⁻CD56⁺	CXCR3+ in CD3⁻CD56⁺	CXCR4+ in CD3⁻CD56⁺	CX3CR1+ in CD3⁻CD56⁺	NK activity EC50^a
1	30.18	62.53	NE	NE	NE	NE	NE	NE	NE	2.61
2	98.41	0.93	0.40	0.24	98.91	23.01	28.33	49.79	36.79	1.31
3	81.78	16.28	17.15	0.96	96.70	20.84	48.80	21.98	28.33	1.31
4	98.75	0.91	0.55	0.13	96.28	29.47	36.67	29.78	28.37	1.61
5	72.84	26.50	25.49	1.87	99.59	68.39	44.82	20.32	39.51	0.63
6	95.67	3.93	3.12	0.30	99.36	60.70	56.62	23.31	42.07	0.62
7	86.25	13.27	3.87	0.24	95.20	50.29	29.04	31.34	26.79	1.39
8	96.60	2.27	2.25	0.07	98.54	60.46	42.90	62.89	50.40	1.24
9	84.91	14.91	10.31	2.64	98.17	72.33	41.80	37.88	62.01	0.98
10	65.94	38.83	33.61	0.23	98.67	62.79	44.04	42.40	51.40	1.88
11	98.49	1.39	0.45	0.11	99.45	69.23	49.69	69.29	44.33	1.76
12	78.52	21.40	11.43	0.30	97.88	73.50	61.05	37.54	70.20	1.99
13	97.23	2.57	2.60	0.11	99.00	32.88	57.66	49.55	54.89	0.59
14	99.45	0.44	0.28	0.09	97.82	63.59	46.12	43.73	43.15	0.39
Median (all enrolled patients)	90.96	8.60	3.12	0.24	98.54	60.70	44.82	37.88	43.15	1.31
Median (ITT population)	90.96	8.60	3.50	0.24	98.36	61.75	45.47	37.71	43.74	1.28

^aThe data are presented for EC50, which means the values corresponding to the E:T ratio needed to reduce the cytotoxicity by 50 % from maximum lysis